On May 6, 2020, BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the closing of the Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) acquisition through an all-stock transaction. The merger agreement was first announced on January 16, 2020. The new subsidiary based in Cambridge, Massachusetts, will operate under the name of BioNTech US Inc. and serve as BioNTech’s U.S. headquarters. As of May 7, 2020, Neon’s common stock will no longer be available for trading.
Duff & Phelps served as an independent financial advisor to the board of directors of Neon Therapeutics, Inc. and provided a fairness opinion in connection with the transaction.
About Neon Therapeutics, Inc.
Neon Therapeutics, Inc. is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Goodwin Procter LLP served as a legal advisor to Neon Therapeutics, Inc.
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. Covington & Burling LLP served as a legal advisor to BioNTech.
Fairness and Solvency Opinions
Independent opinions for boards of directors and special committees.
Transaction Advisory Services
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Corporate Finance and Restructuring
Comprehensive corporate finance, investment banking, restructuring and insolvency services to investors, asset managers, companies and lenders.
Healthcare expertise for middle-market M&A transactions.
Strategic Value Advisory
Assistance evaluating strategic alternatives and identifying growth strategies.
European Chemicals Update – Q4 2021
Insider Threat Indicators and Detection: When Employees Turn Ransomware Accomplices
Valuation Insights – Fourth Quarter 2021
Shannon Pratt’s "Valuing a Business" - Preserving a Legacy
Kroll Unifies Brand to Reflect Strategic Growth and Vision
Kroll Appoints David Lewis, Former Executive Secretary of the FATF, as a Managing Director to Lead its AML Advisory Practice
Who’s Who Legal Recognizes Six Kroll Professionals in the Fields of Financial Restructuring and Insolvency Worldwide
Prime Clerk, A Kroll Business, Welcomes Former Kirkland & Ellis Partner Brad Weiland to Its Team